drugset / Trial / NCT06910072
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
Phase 2/3
Not yet recruiting
32 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.
Timeline
- Start
- 2025-04-02
- Primary completion
- 2026-10-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | iparomilimab | Unknown | 5 mg/kg | — |
| Subject | paclitaxel polymeric micelles | Unknown | 300 mg/m2 | — |